Dr Richard Mead

BSc, MSc, PhD

Department of Neuroscience

Senior Lecturer

r.j.mead@sheffield.ac.uk
+44 114 222 2256
+44 114 222 2278 (Administrator: Heather Cartledge)

Full contact details

Dr Richard Mead
Department of Neuroscience
385a Glossop Road
Sheffield
S10 2HQ
Profile

2019-present Knowledge Exchange and Innovation Lead- Faculty of Medicine, Dentistry and Health

2018-present Senior Lecturer in Translational Neuroscience, Sheffield Institute for Translational Neuroscience

2017-present Co-Founder and Chief Scientific Officer - Keapstone Therapeutics (UoS spin-out)

2013 -2018: Kenneth Snowman-MND Association Lecturer in Translational Neuroscience

2010- 2013: SITraN Senior Research fellow in Translational Neuroscience, University of Sheffield, UK.

2005-2010: Postdoctoral Research Fellow, University of Sheffield, UK.

2002-2004: Pharmacology Team leader, Celltech/UCB, Cambridge, UK.

2001-2002: Postdoctoral research assistant, Department of Biochemistry, University of Wales College of Medicine, Cardiff, UK.

1998-2001: PhD (Neuroimmunology), University of Wales College of Medicine, Cardiff, UK.

Research interests

Research focused on drug discovery in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS), and Parkinson’s disease from target identification to in vivo disease model testing and development of translational biomarkers for early clinical studies. Specific areas include:

  • Pharmacological manipulation of in vitro and in vivo model systems to dissect mechanisms in MND and find new targets
  • Small molecule drug development for inflammatory and oxidative stress targets including NRF2 pathway activators
  • Improving screening methodologies, evolving new in vivo screening paradigms with improved welfare, reduced biological variation and faster throughput
  • Identification of ‘translational’ biomarkers, applicable in both preclinical and clinical settings
  • Investigating novel cell therapy paradigms in MND/ALS

A large proportion of the work in my group is conducted in collaboration with Pharma and Biotech.

I am also co-founder and CSO of Keapstone Therapeutics, a spin-out from the University of Sheffield investigating KEAP1 inhibitors for disease modification in ALS and PD.

Publications

Journal articles

Research group
  • Matthew Stopford, Postdoctoral Research Associate
  • Nora Markus, Postdoctoral Research Associate
  • Sophie Nyberg, Postdoctoral Research Associate
  • Trong Khoa Pham, Postdoctoral Research Associate
  • Sophie Badger, Research assistant
  • Amy Keerie, Phd Student
  • Maria Plesia PhD Student (second supervisor)
  • Isaac Kirkland, Placement Student
Grants
  • Parkinsons UK
  • Medical Research Council
  • Motor Neuron Disease Association, UK
  • University of Sheffield IP development and commercialisation fund
  • Industry funders – Heptares Therapeutics, BenevolentAI, Aclipse Therapeutics
Teaching activities

I teach on the MSc courses in Translational Neuroscience, Translational Neuropathology and co-lead two modules on Masters level courses running in SITraN. My teaching focusses on preclinical study design, analysis of motor function, statistics and drug development.